LOBEF (Lobe Sciences) Payments of Debt: $0.00 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LOBEF Lobe Sciences Ltd LOBEF
16 GF Score
Price $0.08
! 2 Warning Signs
View Full Analysis

What is Lobe Sciences Payments of Debt?

Lobe Sciences LOBEF -1.00% 16 Payments of Debt is $0.00 Mil as of Feb. 2026. GuruFocus rates LOBEF with a GF Score™ of 16/100. The stock has 2 warning signs investors should review.

Lobe Sciences's Payments of Debt for the three months ended in Feb. 2026 was $0.00 Mil.

Lobe Sciences's Payments of Debt for the trailing twelve months (TTM) ended in Feb. 2026 was $0.00 Mil.

Lobe Sciences Payments of Debt Related Terms

Lobe Sciences Payments of Debt Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences Payments of Debt Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 0.00 0.00 0.00 0.00

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LOBEF
16GF Score
Lobe Sciences Ltd LOBEF
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lobe Sciences Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
Lobe Sciences (LOBEF) has a Payments of Debt of $0.00 Mil as of Feb. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Lobe Sciences and its competitors.
Is Lobe Sciences' Payments of Debt too high?
Lobe Sciences' current Payments of Debt is $0.00 Mil. Overall, Lobe Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Lobe Sciences' Payments of Debt compare to VRTX and REGN?
Lobe Sciences' Payments of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Lobe Sciences and its competitors. Lobe Sciences's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current Payments of Debt of $0.00 Mil. The current Payments of Debt is $0.00 Mil. Lobe Sciences' overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current Payments of Debt is $0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBE:GermanyLOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.
16GF Score

Get the complete analysis for LOBEF

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price